On Monday, August 12, the next meeting of the Transparency Council.
The agenda includes:
1 Prepare an opinion on the transfer of the active substance lapatinib from the drug program: B.9. "Treatment of patients with breast cancer (ICD-10: C50)" to the catalog of reimbursed drugs in chemotherapy.
2 Prepare an opinion on the transfer of the active substance cabazitaxel from the drug program: B.56. "Treatment of patients with ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
